Clinical Trials for Cancer Care
KRMC’s WL Nugent Cancer Center is the only cancer treatment center in Mohave County to offer clinical trials for cancer. Our facility is partnered with the National Cancer Institute’s Community Oncology Research Program (NCORP), a national network dedicated to bringing cancer clinical trials to people in their own communities.
What is a clinical trial?
Clinical trials are scientific studies that evaluate the effectiveness of new medical treatments, which can include:
• New drugs that have not yet been approved by the Food and Drug Administration (FDA)
• New uses for drugs that are already approved
• New technologies, such as a new type of radiation therapy
• New ways to combine treatments
After a new medical treatment is thoroughly tested for safety, a clinical trial is done to see how the treatment works on real patients. The patient's safety is a top priority in all phases of clinical trials. When a patient volunteers for a clinical trial, their doctor will determine if it is safe and appropriate for their condition. If so, they can enroll and begin the treatment.
Researchers compare data from clinical trials to data from the standard treatment, or the treatment currently in use. They will monitor the patient’s condition throughout the trial to see if the new treatment is more effective or improves patient outcomes compared to the standard treatment. If the new treatment shows benefits over the standard treatment, it may go on to become the standard treatment.
Clinical trials can offer cancer patients the opportunity to try the newest and most advanced treatments in medical science, which are not yet available to the public. This research also benefits future patients.
Who can participate in clinical trials?
To participate in a clinical trial, a patient must meet certain criteria specific to that trial. For example, a trial could be limited to people of a certain age or with a particular medical condition. This is to make sure that only people who can safely take part in the clinical trial are included.
The patient, their doctor, and the research team will discuss benefits and disadvantages of a given trial to determine whether it is appropriate for the patient. All trials are voluntary. Patients may discontinue a trial at any time and will still receive the best possible care for their condition.
What trials are available?
The WL Nugent Cancer Center is currently recruiting patients with various conditions for clinical trials.
Advanced Melanoma
Study name: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Description: Researchers at the WL Nugent Cancer Center are conducting a Phase III clinical trial for treating advanced melanoma that has been shown to have a BRAFV600 mutation and has spread beyond its local area and cannot be surgically removed.
Study identifier: KRMC 0196 EA6134 NCT02224781
Status: Open
Colorectal Cancer
Study name: Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Description: Researchers at the WL Nugent Cancer Center are conducting a Phase III clinical trial to determine if a higher dose of vitamin D3 in combination with standard chemotherapy and immunotherapy medications possibly improves patient outcomes.
Study identifier: KRMC 0213 A021703 NCT04094688
Status: Open
Cancer Patients who Contract COVID-19
Study name: Observational Study of Cancer Patients who Contract COVID-19
Description: Researchers at the WL Nugent Cancer Center are conducting an observational study of cancer patients who contract COVID-19 to better understand how cancer affects COVID-19 and how COVID-19 affects cancer treatment outcomes.
Study identifier: KRMC 0218 NCI COVID NCT04387656
Status: Open
Lung Cancer in Adults over Age 70
Study name: Older Non-Small Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist’s/Patient’s Choice)
Description: Researchers at the WL Nugent Cancer Center are conducting a clinical trial that involves adults age 70 and over who have non-small cell lung cancer that has spread to other parts of the body. Patients will receive immunotherapy medication (pembrolizumab), which uses your body’s immune system to fight cancer. The goal of the study is to better understand the effectiveness of immunotherapy and possible side-effects in older adults.
Study identifier: KRMC 0236 A041702 NCT03737981
Status: Open
Lymphocytic Leukemia in Older Patients
Study name: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Description: Researchers at the WL Nugent Cancer Center are conducting a Phase III clinical trial to determine if a new combination of FDA-approved medications possibly improves outcomes for untreated older patients (≥ 70 years of age) with chronic lymphocytic leukemia.
Study identifier: KRMC 0169 EA9161 NCT03701282
Status: Open
Lymphocytic Leukemia in Younger Patients
Study name: A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Description: Researchers at the WL Nugent Cancer Center are conducting a Phase III clinical trial to determine if a new combination of FDA-approved medications possibly reduces treatment time for patients with chronic lymphocytic leukemia.
Study identifier: KRMC 0169 EA9161 NCT03701282
Status: Closed to Accrual
Molecular Analysis for Therapy Choice (MATCH) for Non-Responsive or Rare Cancers
Study name: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Description: In collaboration with the National Cancer Institute (NCI), the WL Nugent Cancer Center is participating in a ground-breaking study called NCI-MATCH. This is one of the first major clinical trials to match people who have cancer with treatment based on genetic changes in their tumor rather than their type of cancer.
Study identifier: KRMC 0222 EAY131 NCT02465060
Status: Open
Neuroendocrine Tumors
Study name: A Randomized, Double-Blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CABINET)
Description: Researchers at the WL Nugent Cancer Center are conducting a Phase III clinical trial to determine if the chemotherapy medication cabozantinib is effective for treating neuroendocrine tumors (cancer in neuroendocrine cells that can occur anywhere in the body).
Study identifier: KRMC 0170 A021602 NCT03375320
Status: Open
NSCLC Lung Cancer
Study name: INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature‐driven Analysis
Description: Researchers at the WL Nugent Cancer Center are conducting a clinical trial for treating non-squamous, non-small cell lung cancer (NSCLC) to determine if early treatment with an immunotherapy medication improves patient outcomes. Immunotherapy medications use your body’s immune system to fight cancer. Additionally, the study assesses whether additional treatment with chemotherapy following immunotherapy alone also improves overall survival for patients with NSCLC.
Study identifier: KRMC 0183 EA5163/S1709 NCT03793179
Status: Open
Prostate Cancer Survivors
Study name: Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy
Description: Researchers at the WL Nugent Cancer Center are conducting a Phase II clinical trial to determine how survivorship care planning can best improve follow-up care and outcomes for patients with prostate cancer after they have completed cancer treatment.
Study identifier: KRMC 0212 NRGCC007CD NCT03860961
Status: Open
Smoldering (Pre-Cancerous) Myeloma
Study name: IDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Description: Researchers at the WL Nugent Cancer Center are conducting a Phase III clinical trial for treating smoldering myeloma to determine if patient outcomes improve when taking an immunotherapy medication (called daratumumab) combined with standard chemotherapy treatment. Immunotherapy medications use your body’s immune system to fight cancer.
Study identifier: KRMC 0182 EAA173 NCT03937635
Status: Open
Squamous Cell Skin Cancer
Study name: Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Description: Researchers at the WL Nugent Cancer Center are conducting a Phase II clinical trial for treating advanced skin squamous cell cancer using the immunotherapy medications: avelumab and cetuximab. Immunotherapy medications use your body’s immune system to fight cancer.
Study identifier: KRMC 0194 A091802 NCT03944941
Status: Open
Tissue & Blood Donation for Cancer Research
Study name: The Cancer Moonshot Biobank
Description: Cancer treatments don’t work the same way for everyone – samples from many different communities will help us understand why this is and how to improve care. Through the Cancer Moonshot Biobank, researchers plan to collect, store, and study tissue samples donated by more than 1,000 people with cancer.
Study identifier: KRMC 0232 10323/NCI-2020-00750 NCT04314401
Status: Open
Please talk to your doctor if you think a clinical trial may be right for you.